key: cord-0745826-afpbaqgx authors: Chen, Ji‐Ming; Sun, Ying‐Xue; Chen, Ji‐Wang title: Potential for elimination of SAR‐CoV‐2 through vaccination as inspired by elimination of multiple influenza viruses through natural pandemics or mass vaccination date: 2020-06-11 journal: J Med Virol DOI: 10.1002/jmv.26162 sha: c23a272c8781c0a176066df557216735828e7cf4 doc_id: 745826 cord_uid: afpbaqgx The ongoing pandemic of coronavirus disease 2019 (COVID‐19) caused by the novel virus SARS‐CoV‐2 has claimed many lives worldwide. To combat the pandemic, multiple types of vaccines are under development with unprecedented rapidity. Theoretically, the future vaccination against COVID‐19 may fall into long‐term costly guerrilla warfare between SARS‐CoV‐2 and humans. Elimination of SARS‐CoV‐2 through vaccination to avoid the potential long‐term costly guerrilla warfare, if possible, is highly desired and worth intensive consideration. Human influenza pandemics emerging in 1957, 1968, and 2009 established strong global herd immunity and led to elimination of three human influenza viruses which circulated worldwide for years before the pandemics. Moreover, both clade 7.2 of subtype H5 highly pathogenic avian influenza virus and subtype H7N9 avian influenza virus circulated in poultry in China for years, and they have been virtually eliminated through mass vaccination in recent years. These facts suggested that rapid establishment of global herd immunity through mass vaccination using a proper vaccine could eliminate SARS‐CoV‐2. The coming two years is the golden time for the elimination through vaccination which requires tremendous national and international collaboration. This review also prioritized the efficacy of vaccines for COVID‐19 and elucidated the importance for development of more live vaccines for COVID‐19. This article is protected by copyright. All rights reserved. Even if a safe and effective vaccine shall be marketed in months, vaccination against COVID-19 may fall into long-term guerrilla warfare between SARS-CoV-2 and humans. First, after the pandemic, COVID-19 could be as mild as human diseases caused by other human coronaviruses, or as severe as the coronavirus diseases in swine, chicken, feline, and murine which are all more burdensome than influenza. 3 Second, SARS-CoV-2 could escape vaccination through its rapid mutation including site substitutions, genomic recombination, and open reading frame shift. 4 Third, SARS-CoV-2 could move swiftly through the movement of infected people, and hide in some people for weeks without symptoms. 5 Fourth, the hidden SARS-CoV-2 could attack unpredictably susceptible humans who have not been infected or vaccinated, or have no sustainable immunity induced by the infection or vaccination, or have innate or acquired immunodeficiency. Vaccination could accelerate the mutation of viruses through natural selection, and SARS-CoV-2 could diverge into distinct lineages through its rapid mutation, both of which could escalate the guerrilla warfare between SARS-CoV-2 and humans. Accordingly, the vaccine should be updated promptly to match the mutated virus, and multiple vaccine strains or antigens should be used to match major diversified lineages of the virus. The vaccination, update of the vaccine, and addition of vaccine strains or antigens could be all highly burdensome. Difficulty in vaccine development, rapid mutation of coronaviruses, long-term guerrilla warfare between viruses and humans, and heavy disease burden have been demonstrated in animal coronavirus diseases. 3 The above information suggests that elimination of SARS-CoV-2 through vaccination to avoid the potential long-term costly guerrilla warfare, if possible, is highly desired and worth extensive discussion and intensive consideration. Moreover, This article is protected by copyright. All rights reserved. the elimination initiative is inspired by the interesting history that multiple influenza viruses have been eliminated through natural pandemics or mass vaccination, as explained below. During the past seven decades, three human influenza viruses (HuIVs) disappeared coincidently with emergence of three influenza pandemics. 7 First, the H1N1 subtype HuIV, which circulated in humans for many years before 1957, disappeared during the pandemic of H2N2 subtype HuIVs emerging in 1957. Second, the above H2N2 subtype HuIV, which circulated for approximately ten years after 1957, disappeared during the pandemic of H3N2 subtype HuIV emerging in 1968. Third, the H1N1 subtype HuIV, which circulated after its re-emergence in 1977, disappeared during the pandemic of swine-origin H1N1 subtype HuIV emerging in Disappearance of the above three HuIVs can be explained only by the broad and strong herd immunity induced by the relevant pandemic viruses, in statistics and in biology. 7 This means that the pandemics provided natural, rapid, global, and highly effective vaccination which eliminated the three HuIVs having circulated in humans for years. The pandemic viruses harbored multiple genes from the eliminated viruses, or shared the same HA and NA subtypes with the eliminated viruses (Table 1 ). 8 They thus shared various T and/or B cell epitopes with the eliminated viruses, and so the immunity induced by the pandemic viruses exerted the elimination effect. The above elimination events demonstrated that the pandemic viruses, although disastrous, induced broader and stronger herd immunity than commercial influenza vaccines which could reduce infections caused by limited clades of HuIVs within the same HA subtype. The pandemic of swine-origin H1N1 HuIV in 2009 did not eliminate the H3N2 subtype HuIV which has circulated since 1968, possibly because these two viruses did not harbor any genomic segments (Table 1) , although the PB1 gene of the pandemic virus was from H3N2 subtype HuIVs circulating approximately ten years before 2009, 8 and they thus shared less T and/or B cell epitopes. In 1977, the H1N1 HuIV This article is protected by copyright. All rights reserved. which circulated in the 1950s re-emerged worldwide possibly due to a laboratory incident, and most infected people were under 23 who had not encountered the H1N1 HuIV before 1977. 9 Therefore, re-emergence of the H1N1 HuIV induced lower herd immunity than the above pandemics, and thus did not eliminate the above H3N2 HuIV either. Deliberate vaccination has also eliminated an AIV. 10 The mechanism of elimination of the three HuIVs and two AIVs is that strong immunity was induced in almost all susceptible hosts in affected areas against the targeted virus through natural or deliberate vaccination in a relatively short time, 14 and the established herd immunity blocked the circulation of a targeted virus completely. These events indicate that elimination of COVID-19, which is also a respiratory infectious disease caused by an RNA virus, is possible and should be based on rapid establishment of global herd immunity through mass vaccination. Theoretically, the coming two years is the golden time for elimination of SARS-CoV-2 through vaccination, because SARS-CoV-2 shall likely have not diversified into distinct lineages during this period, and thus one vaccine strain or antigen could match all lineages of SARS-CoV-2 circulating worldwide. 6 Moreover, many people shall have been infected in the coming months by SARS-CoV-2, which aids to establish strong herd immunity for the elimination. Elimination of COVID-19 through vaccination should be a great project requiring tremendous national and international collaboration (Figure 1) , and the elimination project is of the vital interests of all countries as it saves much money and many lives for all countries. Moreover, most people in the world have known the risk of COVID-19 and could actively aid or involve the elimination. China government has pledged to donate two billion USD to the world to fight COVID-19, and such donations could support strongly this elimination project. We assessed preliminarily that the benefit/cost ratio of the elimination could be over ten, because the elimination This article is protected by copyright. All rights reserved. through vaccination required about three-fold efforts for common vaccination in a year, and the elimination could remove over 30 years of heavy burden caused by . Even if the disease has not been eliminated through tremendous efforts, the elimination efforts should remain highly valuable because it could be beneficial for better control of the disease. The relevant international cooperation mechanism should be established for the global elimination project. All countries should collaborate with unprecedented solidarity to fully discuss this issue, rationally design the route map, and actively deploy resources to implement the project. Lessons and experiences of the past in vaccination against other viral infectious diseases should be well considered in the project design. The vaccine for the elimination project should be carefully selected. The vaccine should be safe, effective, inexpensive, rapid in production, easy for storage, and convenient for vaccination, but few vaccines meet all these requirements. 2 Table 2 shows presumed advantages and disadvantages of major types of vaccines with exceptions (e.g. some live attenuated vaccines including those for poliomyelitis and mumps are safe for use). 15 Critically, sometimes higher vaccine efficacy means lower safety risk due to lower morbidity. For example, vaccine B should be superior to vaccine A, if vaccine A is of 100% safety and reduces symptomatic COVID-19 cases by 60% from 5.0% to 2.0% of the vaccinated population, and vaccine B reduces symptomatic cases caused by natural infection by 100%, although 0.2% of the people inoculated with vaccine B become symptomatic COVID-19 cases caused by the vaccine. Moreover, almost all the few vaccine-associated cases can be cured, like that 99.84% of the cases in China beyond the province Hubei, who were treated timely, successfully recovered. 16 Therefore, unlike the vaccines for rabies and polio, efficacy of COVID-19 vaccines could be prioritized. codon-modification could reduce the pathogenesis rapidly, but whether the LAV can be generated and propagate efficiently in cells is of concern because it employs many rare codons. 2 Considering that LAVS are of multiple potential advantages and various successful applications, more types of LAVs should be developed for COVID-19. The elimination history of the three HuIVs suggests that LPV can induce broad and strong immunity, because the relevant pandemic influenza viruses could be considered as LPVs which eliminated the relevant HuIVs. The LPV strategy has been applied successfully in the USA military recruits for nearly 40 years to control acute respiratory diseases caused by types 4 and 7 adenoviruses, and reduced the morbidity by over 99%. 18 It avoids causing disease through oral administration of enteric-coated capsules containing the LPV to bypass the pathogenic site of the fragile lungs. 19 Beyond inducing broad and strong immunity, LPVs are of no concern about pathogenic reversion and inhibit indirectly the mutation and diversification of the targeted virus through replacing various virus mutants circulating in vaccinated regions. 20 Although the safety of the LPV strategy is a big public concern, the safety has been well guaranteed in the LPV of adenovirus used in the USA military recruits, and can be further guaranteed with novel measures. 20 Detailed plans should be formulated to guide the global elimination project. Over half people worldwide should be vaccinated in a relatively short time to establish the strong herd immunity. Considering the rate of the vaccine production and risk factors of COVID-19, elderly people and healthcare workers should be vaccinated first. 21 The This article is protected by copyright. All rights reserved. mass vaccination is favorably conducted in warm or hot seasons when the prevalence of many infectious viruses including COVID-19 is lower and human immunity is higher than in cold seasons. 22 Moreover, epidemiological monitoring system should be well designed and established to identify potential problems associated with the global elimination project, and scientific solutions to these problems should be prepared in advance. If successful, this global elimination project could pave the road for elimination of some other viral infectious diseases. It shall also greatly enhance global solidarity which is the core fortune of mankind. The COVID-19 vaccine development landscape This article is protected by copyright. All rights reserved The race for coronavirus vaccines: a graphical guide COVID-19 from veterinary medicine and one health perspectives: What animal coronaviruses have taught us Identification of the mechanisms causing reversion to virulence in an attenuated SARS-CoV for the design of a genetically stable vaccine Rapid development of an inactivated vaccine candidate for SARS-CoV-2 Follow-up of asymptomatic patients with SARS-CoV-2 infection Why do influenza virus subtypes die out? A hypothesis Diversity and distribution of type A influenza viruses: an updated panorama analysis based on protein sequences The re-emergence of H1N1 influenza virus in 1977: a cautionary tale for estimating divergence times using biologically unrealistic sampling dates Control of avian influenza in China: Strategies and lessons Characterization of clade 7.2 H5 avian influenza viruses that continue to circulate in chickens in China This article is protected by copyright. All rights reserved Subclinical highly pathogenic avian influenza virus infection among vaccinated chickens Vaccination of poultry successfully eliminated human infection with H7N9 virus in China Herd immunity and a vaccination game: An experimental study The vaccine book COVID-19) mortality rate Centers for Disease Control and Prvention. Vaccines and preventable diseases Safety evaluation of adenovirus type 4 and type 7 vaccine live, oral in military recruits Immunization with types 4 and 7 adenovirus by selective infection of the intestinal tract Potential of live pathogen vaccines for defeating the COVID-19 pandemic: history and mechanism Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study This article is protected by copyright. All rights reserved We thank Meng Yang for her helpful advice and assistance. The authors declare there are no conflict of interests. JmC, YxC, and JwC designed and wrote this article, and JmC made the major conclusions. The data supporting the views of this article are available from the corresponding author on request. The article does not contain the participation of animals and humans other than the authors.